Literature DB >> 22874607

Hypoxia-related proteins in patients with rectal cancer undergoing neoadjuvant combined modality therapy.

Steven A Lee-Kong1, Jeannine A Ruby, David B Chessin, Salvatore Pucciarelli, Jinru Shia, Elyn R Riedel, Donato Nitti, José G Guillem.   

Abstract

BACKGROUND: We have previously demonstrated the prognostic significance of rectal cancer pathologic response to neoadjuvant chemoradiation. Recent studies in other cancers have reported that hypoxia influences response to neoadjuvant chemoradiation.
OBJECTIVE: This study aimed to 1) characterize hypoxia-related protein expression in locally advanced rectal cancer before neoadjuvant chemoradiation, 2) determine the comodulation of hypoxia-related protein expression, and 3) evaluate the relationship between hypoxia-related protein expression and overall survival, time to recurrence, and tumor regression grade.
DESIGN: Immunohistochemical analysis of 4 hypoxia-related proteins (HIF-1α, CA-IX, VEGF, and GLUT-1) was performed on archival pretreatment rectal cancer biopsies. PATIENTS: : Eighty-five patients with locally advanced rectal cancer treated with neoadjuvant radiation and 5-fluorouracil-based chemotherapy were included. MAIN OUTCOME MEASURES: The impact of hypoxia-related protein expression on outcome was evaluated by use of Cox proportional hazards model. Hypoxia-related protein expression was correlated with tumor regression grade by use of Spearman correlation coefficients.
RESULTS: Median follow-up was 54 months. CA-IX expression was associated with overall survival (p = 0.01). HIF-1α expression was weakly correlated with VEGF (r = 0.26, p = 0.02) and GLUT-1 (r = 0.35, p = 0.001). Hypoxia-related protein expression was not associated with time to recurrence or Mandard tumor regression grade.
CONCLUSIONS: Elevated CA-IX expression may be associated with poorer overall survival in locally advanced rectal cancer treated by neoadjuvant chemoradiation and resection. The expression of the hypoxia-related proteins HIF-1α, VEGF, and GLUT-1 may be comodulated in locally advanced rectal cancer. Further studies are needed to evaluate the mechanisms governing hypoxia regulation and the role of hypoxia in rectal cancer response to neoadjuvant chemoradiation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22874607     DOI: 10.1097/DCR.0b013e31825bd80c

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  12 in total

1.  Angiogenic regeneration defines loco-regional recurrence following pre-operative radio-chemotherapy for rectal cancer: a pilot study.

Authors:  Michael I Koukourakis; Ioannis M Koukourakis; Stella Arelaki; Maria Kouroupi; Spyros Domoxoudis; Alexandra Giatromanolaki
Journal:  Mol Biol Rep       Date:  2019-02-05       Impact factor: 2.316

2.  Selecting patients for hyperthermia combined with preoperative chemoradiotherapy for locally advanced rectal cancer.

Authors:  Sang-Won Kim; Ji Woon Yea; Jae Hwang Kim; Mi Jin Gu; Min Kyu Kang
Journal:  Int J Clin Oncol       Date:  2017-11-13       Impact factor: 3.402

3.  Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer.

Authors:  Walid K Chatila; Jin K Kim; Henry Walch; Michael R Marco; Chin-Tung Chen; Fan Wu; Dana M Omer; Danny N Khalil; Karuna Ganesh; Xuan Qu; Anisha Luthra; Seo-Hyun Choi; Yu-Jui Ho; Ritika Kundra; Katharine I Groves; Oliver S Chow; Andrea Cercek; Martin R Weiser; Maria Widmar; Iris H Wei; Emmanouil P Pappou; Garrett M Nash; Philip B Paty; Qian Shi; Efsevia Vakiani; S Duygu Selcuklu; Mark T A Donoghue; David B Solit; Michael F Berger; Jinru Shia; Raphael Pelossof; Paul B Romesser; Rona Yaeger; J Joshua Smith; Nikolaus Schultz; Francisco Sanchez-Vega; Julio Garcia-Aguilar
Journal:  Nat Med       Date:  2022-08-15       Impact factor: 87.241

4.  Thymidine phosphorylase and hypoxia-inducible factor 1-α expression in clinical stage II/III rectal cancer: association with response to neoadjuvant chemoradiation therapy and prognosis.

Authors:  Shuhan Lin; Hao Lai; Yuzhou Qin; Jiansi Chen; Yuan Lin
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

5.  Correlation of 18F-FDG/PET SUVmax, SUVmean, MTV, and TLG with HIF-1α in Patients with Colorectal Cancer

Authors:  Zümrüt Arda Kaymak; Nermin Karahan; Mehmet Erdoğan; Evrim Erdemoğlu; İsmail Zihni; Sevim Süreyya Şengül
Journal:  Mol Imaging Radionucl Ther       Date:  2021-06-03

6.  Expression of hypoxic marker carbonic anhydrase IX predicts poor prognosis in resectable hepatocellular carcinoma.

Authors:  Wei-Ju Huang; Yung-Ming Jeng; Hong-Shiee Lai; Iok-U Fong; Fang-Yu Bonnie Sheu; Po-Lin Lai; Ray-Hwang Yuan
Journal:  PLoS One       Date:  2015-03-04       Impact factor: 3.240

7.  Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer.

Authors:  Helga Helseth Hektoen; Kjersti Flatmark; Yvonne Andersson; Svein Dueland; Kathrine Røe Redalen; Anne Hansen Ree
Journal:  BMC Cancer       Date:  2015-07-24       Impact factor: 4.430

8.  DPYD, TYMS, TYMP, TK1, and TK2 genetic expressions as response markers in locally advanced rectal cancer patients treated with fluoropyrimidine-based chemoradiotherapy.

Authors:  Ming-Yii Huang; Chan-Han Wu; Chun-Ming Huang; Fu-Yen Chung; Ching-Wen Huang; Hsiang-Lin Tsai; Chin-Fan Chen; Shiu-Ru Lin; Jaw-Yuan Wang
Journal:  Biomed Res Int       Date:  2013-12-23       Impact factor: 3.411

9.  Dexamethasone downregulates expression of carbonic anhydrase IX via HIF-1α and NF-κB-dependent mechanisms.

Authors:  Veronika Simko; Martina Takacova; Michaela Debreova; Katarina Laposova; Elena Ondriskova-Panisova; Silvia Pastorekova; Lucia Csaderova; Jaromir Pastorek
Journal:  Int J Oncol       Date:  2016-07-14       Impact factor: 5.650

Review 10.  Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis.

Authors:  Simon J A van Kuijk; Ala Yaromina; Ruud Houben; Raymon Niemans; Philippe Lambin; Ludwig J Dubois
Journal:  Front Oncol       Date:  2016-03-29       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.